NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

And the maker of that treatment, Autolus, is worth less than NWBO on the market.

Take a look at their valuation since approval. -67% since November 8 with obe-cel was approved.

Still, no one believes that these biotechs can go down after approval. Down another 4% on announcing obe-cel approval in the UK.

Obviously different markets and competitive landscapes, but if you think it's impossible for NWBO to go down upon announcing approval, you are not paying attention.